用户,您好!欢迎您进入重大新药创制—政策信息平台!登录 | 注册  NSTL重点领域信息门户  帮助中心  RSS
 您当前的位置: 首页 > 资源详细信息
资源基本信息 
发布日期: Jul 17, 2019
资源类型: 75.8KB
资源性质: 最新消息
重要度:  
资源评价:

资源推荐:

对象相关资源
同目录资源
系统抽取对象
机构     
(1)
(1)
(1)
(1)
(1)
(1)
(0)
(4)
(1)
(1)
(1)
(3)
主题词
其他     
(1)
(1)
(3)
社会事件     
(1)
人物     
(1)
(1)
(1)

Regulatory News

FDA Seeks Comment on ICH Guideline on Optimizing Safety Data Collection. Posted 16 July 2019 By Zachary Brennan   The US Food and Drug Administration (FDA) recently opened for comment until 26 August a guideline from the International Council for Harmonisation (ICH) on how to collect safety data in some late-stage pre-approval or post-approval studies when the safety profile of a drug is sufficiently characterized. The 10-page draft of E19, endorsed by the ICH Assembly on 3 April, is part of efforts to reduce the burden on study participants while facilitating studies that can advance public health. The guideline notes the types of safety data where it may be appropriate to limit or stop collection, which could include non-adverse events, routine laboratory tests, information on concomitant medications, physical examinations (including vital signs) or electrocardiograms. But the guideline also describes the types of safety data that should always be collected, including deaths, serious or significant adverse events, overdoses and several other categories. “When sponsors choose to implement selective safety data collection for a clinical study, a scientific justification should be provided,” the guideline says, noting specific factors that would be appropriate in making such a determination. Such factors could help speed to market a medicinal product under investigation that has received a marketing authorization from a regulatory authority in the same indication as the one under investigation. The guideline also lists examples of when selective safety data collection may be considered, such as when it’s a new indication of an approved drug or if it’s a demonstration of superiority when non-inferiority has been demonstrated. Changes to a selective safety data collection approach may be warranted in some circumstances, the guideline notes, such as when there is a postmarketing safety signal or there’s a concern from a data monitoring committee. The guideline further describes methods of implementation, such as when selective safety data collection is done for all patients in a study, when it’s for a specific subset of a population or when comprehensive safety data is collected for the initial portion of a study but then selective data is collected afterward. Mary Thanh Hai, director of the Office of Drug Evaluation II at FDA, said in April that ICH’s expert working group plans to meet next fall to review public comments on E19, and in June 2021, the guideline is slated to reach Step 4. E19 OPTIMISATION OF SAFETY DATA COLLECTION .